Osteoporosis and obesity: Role of Wnt pathway in human and murine models

Graziana Colaianni, Giacomina Brunetti, Maria Felicia Faienza, Silvia Colucci, Maria Grano

Abstract
Studies concerning the pathophysiological connection between obesity and osteoporosis are currently an intriguing area of research. Although the onset of these two diseases can occur in a different way, recent studies have shown that obesity and osteoporosis share common genetic and environmental factors. Despite being a risk factor for health, obesity has traditionally been considered positive to bone because of beneficial effect of mechanical loading, exerted by high body mass, on bone formation. However, contrasting studies have not achieved a clear consensus, suggesting instead that excessive fat mass derived from obesity condition may not protect against osteoporosis or, even worse, could be rather detrimental to bone. On the other hand, it is hitherto better established that, since adipocytes and osteoblasts are derived from a common mesenchymal stem cell precursor, molecules that lead to osteoblastogenesis inhibit adipogenesis and vice versa. Here we will discuss the role of the key molecules regulating adipocytes and osteoblasts differentiation, which are peroxisome proliferators activated receptor-γ and Wnts, respectively. In particular, we will focus on the role of both canonical and non-canonical Wnt signalling, involved in mesenchymal cell fate regulation. Moreover, at present there are no experimental data that relate any influence of the Wnt inhibitor Sclerostin to adipogenesis, although it is well known its role on bone metabolism. In addition, the most common pathological condition in which there is a simultaneous increase of adiposity and decrease of bone mass is menopause. Given that postmenopausal women have high Sclerostin level inversely associated with circulating estradiol level and since the sex hormone replacement therapy has proved to be effective in attenuating bone loss and reversing menopause-related obesity, we hypothesize that Sclerostin contribution in adipogenesis could be an active focus of research in the coming years.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Osteoporosis; Obesity; Bone; Fat; Wnt; Peroxisome proliferators activated receptor-γ; Dickkopf; Sclerostin

Core tip: Here we will discuss the role of the key molecules influencing adipocytes and osteoblasts differentiation, which are peroxisome proliferators activated receptor-γ and Wnts, respectively. Besides these proteins, the Wnt inhibitor molecules are also necessary to control the Wnt signalling balance from active to inactive state, in favour of osteogenesis or adipogenesis. It seems remarkably important a deepen analysis of these molecules, not only for their involvement in the regulation of the differentiation processes but also in coordinating the switch toward osteo- or adipogenesis fate within bone marrow.

Colaianni G, Brunetti G, Faienza MF, Colucci S, Grano M. Osteoporosis and obesity: Role of Wnt pathway in human and murine models. World J Orthop 2014; 5(3): 242-246 Available from: URL: http://www.wjgnet.com/2218-5836/full/v5/i3/242.htm DOI: http://dx.doi.org/10.5312/wjo.v5.i3.242
The relevance of the canonical Wnt signaling in bone is well acknowledged and several reports have unanimously established that Wnt/β-catenin activity is essential for bone development\[14\]. Wnts are a highly conserved family of proteins that can operate through two different signaling pathways. In the canonical pathway, when Wnt signaling is active, a multiprotein complex, including adenomatous polyposis coli (APC), glycogen synthase kinase 3 (GSK3) and Axin, induces the degradation of β-catenin, thus releasing the free cytoplasmic pool of β-catenin. When Wnt signal is active through the Frizzled (FZD) receptor and low density lipoprotein receptor-related protein 5 and 6 (LRP5/6) receptor complex, it inactivates GSK3 and causes its dissociation from Axin preventing the phosphorylation of β-catenin. Hence, this pool of β-catenin in the cytoplasm increases and translocates to the nucleus where it binds members of the LEF/TCF family of transcription factors to provoke transcriptional induction of target genes\[14\]. In non-canonical pathway, Wnt signaling is induced through Frizzled independent of LPR5/6. This pathway causes cytoskeletal changes through activation of the small GTPases Rho and Rac\[14\].

Wnt10b, one of Wnt family member, plays a key role in bone formation. It is expressed by osteoblast progenitors in bone marrow\[19\] and, hence, its transgenic overexpression in mesenchymal cells enhances osteoblastogenesis and leads to increased bone density. Accordingly, Wnt10b deficient mice display reduced trabecular bone\[16\] by μCT analysis. Thus, the distal metaphyses of these mice showed a 30% reduction in bone volume/total volume and bone mineral density. This loss was ascribed to a decrease in trabecular number with an associated increase in trabecular spacing. In addition to decreased bone mass in the femur, Wnt10b deficient mice also displayed reduction in bone volume fraction in proximal tibia\[19\].

Furthermore, non-canonical Wnt members may also be involved in regulating osteogenesis. In particular, Wnt5a seems to be the most important Wnt member, acting through non canonical way, that is expressed during osteoblastic differentiation of mesenchymal stem cells\[57\]. Wnt-5a stimulates osteoblast differentiation through an autocrine loop\[18\] and haploinsufficient mice for Wnt-5a display a lower bone mass with decreased osteoblast number\[19\]. Another non-canonical Wnt member with a potential interest in bone accrual is Wnt4. Chang et al\[20\] reported that human mesenchymal stem cells, genetically engineered to express Wnt-4, have enhanced commitment toward osteogenesis. Moreover, the ectopic Wnt-4 expression was able to ameliorate craniofacial defects in two different models of craniofacial bone injury\[21\].

Regarding Wnts functions in adipogenesis, studies of Moldes et al\[21\], demonstrated that transgenic expression of Wnt1 in preadipocyte cell line strongly suppresses adipogenesis. This study also suggests a reciprocal relationship between PPARγ activity and β-catenin expression, since the concomitant over-expression of PPARγ and Wnt-1 in preadipocytes rescued the inhibition of adipogenesis by suppressing β-catenin expression, after the exposure to the PPARγ agonist, troglitazone. Based
on these observations, authors have proposed a model according to which, if Wnt signaling at the early stage of adipogenesis has been lowered to a level that permits induction of PPARγ, this latter, once activated, can further down-regulate β-catenin levels, leading differentiation of mature adipocytes. Likewise, pharmacological treatments that activate Wnt signaling and stabilize free cytosolic β-catenin are able to inhibit preadipocyte differentiation. Conversely, by blocking Wnt signaling in preadipocytes, stimulates their differentiation, suggesting that preadipocytes might synthesize endogenous Wnt molecules. Indeed, it has been shown that Wnt10b is highly expressed in confluent preadipocytes and it is immediately downregulated after exposure to elevated cAMP occurring during adipocyte differentiation. Accordingly, if Wnt-10b is constitutively expressed, it stabilizes cytosolic β-catenin leading to suppression of adipogenesis. On the contrary, Wnt-5b is transiently induced during adipogenesis and destabilizes β-catenin to enhance adipocyte differentiation, indicating that preadipocytes could be targeted by opposite Wnt signals.

While mesenchymal stem cells activate their differentiation process toward adipogenic or osteogenic cell fate, specific transcription factors become up-regulated. These include CCAAT/Enhancer binding protein (C/EBP) alpha and PPARγ for adipocytes and core binding factor alpha 1 (Chlfal/Runx2) for osteoblasts. The reciprocal relationship between adipogenesis and osteoblastogenesis is also dependent on the ability of these lineage-specific transcription factors to inhibit differentiation of other lineages. For example, PPARγ also inhibits terminal osteoblast differentiation by suppressing Runx2 expression.

Canonical vs non-canonical Wnt signalling: How this switch controls mesenchymal stem cell fate

A reversal process, from non-canonical Wnt signaling to canonical Wnt signaling or vice versa, drives the progression into the differentiation stage. Indeed, during early adipogenesis, a prompt activation-inactivation of the Wnt pathway is crucial for the induction of PPARγ. Specifically, the non-canonical Wnt5α pathway induces a signaling, through PPARγ, that regulates differentiation and insulin sensitivity of mature adipocytes. On the other hand, canonical Wnt signaling is responsible for promoting cell proliferation via activation of cyclin D1 and c-myc while inhibiting PPARγ. This accounts for the mechanism involved in keeping pre-adipocytes in an undifferentiated state. Thus, cyclin D1 and c-myc directly bind and inhibit PPARγ and the C/EBPα transcription factor, respectively. At the same time, the expression of C/EBPα leads per se to the phosphorylation of β-catenin and its subsequent degradation. Therefore, nuclear β-catenin activity is down-regulated and non-canonical signaling is switched on in order to promote adipocyte differentiation. Notably, the concomitant induction of PPARγ after β-catenin proteasomal degradation, further suggests that β-catenin could suppress PPARγ expression, as vice versa.

Based on what has been described, it appears questionable how Wnts molecules are capable of exert different stimuli in mesenchymal stem cells. A reasonable explanation might be given considering other molecules involved in the Wnt signaling, that have inhibitory functions.

Wnt signaling inhibitors: Novel perspective in the control of adipogenesis

Wnt signaling can be blocked by secreted antagonists including Dickkopf (DKK) and Sclerostin. DKK1 and Sclerostin inhibit WNT signaling by binding to the co-receptors LDL receptor-related proteins (LRPs) 5 and 6, preventing formation of the active LRP/Frizzled complex. The involvement of DKK1 in adipocyte differentiation has been demonstrated in several experiments. Transfection of human mesenchymal stem cells with DKK1 small interfering RNA reduced adipogenesis. Furthermore, Dkk1 was found to be highly expressed in differentiated 3T3-L1 adipocytes and its expression was enhanced by PPARγ agonists. Therefore, secretion of DKK1 might be the mechanism whereby PPARγ promotes adipogenesis, while inhibiting Wnt signaling.

Sclerostin is the other inhibitor of the powerful bone anabolic Wnt pathway. Targeting deletion of Sclerostin in mice leads to high bone mass, due to a great increase in bone formation in both trabecular and cortical bone. It has been demonstrated that antibody-based sclerostin inhibition increased bone mass and strength in healthy female rats and rescued ovarietomy-induced bone loss. Furthermore, in a model of hindlimb disuse, antibody-based sclerostin inhibition was able to increase cortical and trabecular bone mass either in loaded upper limbs or in immobilized hind limb. This effect was characterized by coupling of high bone formation and decreased bone resorption, suggesting that inhibition of sclerostin might be useful for the treatment of immobilization-induced osteopenia.

Conversely, an important clinical study in the field of rehabilitation, performed enrolling 39 subjects with chronic spinal cord injury and 10 without spinal cord injury, demonstrated that greater total limb bone mineral content was significantly associated with greater circulating levels of Sclerostin. Thus, Sclerostin levels were reduced in subjects with spinal cord injury who use a wheelchair compared to those with spinal cord injury who walk normally. Likewise, Sclerostin levels were lower in patients with spinal cord injury who use a wheelchair compared to persons without spinal cord injury. These results showed that circulating Sclerostin can be used as biomarker of severe osteoporosis, but not as biomarker of bone loss, in long-term absence of mechanical loading.

However, to date it is well known about conditions where Sclerostin is genetically absent, such as in the disease known as Sclerostosis with bone mass markedly enhanced. Conversely, there are currently few notions about the molecular mechanism involved in Sclerostin up-regulation, unless for the knowledge that postmeno-
pausal women have high serum Sclerostin level inversely associated with the circulating free estradiol (E2) index. Furthermore, the reduction in Sclerostin circulating levels after E2 treatment provides a meaning for addressing the key question about the involvement of sex steroid as regulators of Sclerostin expression.

The understanding of the molecular mechanism whereby Estrogen reduces the circulating Sclerostin levels might support the use of an anti-Sclerostin antibody in preventing bone loss, but also in avoiding fat mass augmentation, occurring at the decline of sex hormones. However, nowadays there are few data regarding the relationship between Sclerostin levels and obesity. Only one cross-sectional study, performed by Urano et colleagues aimed to identify the relationship between serum sclerostin levels and markers of metabolic disease. Authors measured serum sclerostin levels in 352 Japanese postmenopausal women and analyzed the relationship of these levels with abdominal fat mass. Their result show that serum Sclerostin levels were positively correlated with percentages of abdominal and gynoid fat.

CONCLUSION

Recently, it has become evident that Wnt family members are key molecules regulating differentiation of multipotent mesenchymal stem cells into osteoblasts and adipocytes, as showed both by animal models and by several clinical studies in humans. Besides Wnt proteins, the Wnt inhibitor molecules are also necessary to control the Wnt signalling balance from active to inactive state, in favour of osteogenesis or adipogenesis. This molecular control could be evidenced crucial in the pathogenesis of obesity, as it is established to be fundamental in osteoporosis. Finally, it seems remarkably important a deepen analysis of these bioactive molecules, not only for their involvement in the regulation of the differentiation processes but also in coordinating the switch toward osteo- or adipogenesis fate within bone marrow.

Moreover, in the view of using the antibody-based sclerostin inhibition, as therapeutic approach to shift the balance in favor of osteogenesis at the expense of adipogenesis, further studies could be extremely relevant in the understanding the role of Sclerostin in regulating adipogenesis. These future studies could likely open an exciting avenue in osteoporosis and obesity research field, which may outcome in the development of novel therapeutic approaches to treat these burden diseases. Therefore, Sclerostin antibody will be extremely useful as skeletal anabolic agents to treat osteoporosis, but might also have potential utility in the therapy of obesity.

REFERENCES

1. Rosen CJ, Bourquin ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006; 2: 35-43 [PMID: 16932650 DOI: 10.1038/ncprheum0070]
2. Colaianni G, Sun L, Di Benedetto A, Tamma R, Zhu LL, Cao J, Grano M, Yuen T, Colucci S, Cusco G, Mancini L, Li J, Nishimori K, Bab I, Lee HJ, Iqbal J, Young WS, Rosen C, Zallone A, Zaidi M. Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton. J Biol Chem 2012; 287: 29159-29167 [PMID: 22761429 DOI: 10.1074/jbc.M112.365049]
3. Manson JE, Martin KA. Clinical practice. Postmenopausal hormone-replacement therapy. N Engl J Med 2001; 345: 34-40 [PMID: 11439947 DOI: 10.1056/NEJM200107053450106]
4. Sørensen MB, Rosenfeld AL, Heijgaard L, Ottesen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes Res 2001; 9: 622-626 [PMID: 11505778]
5. Brunetti G, Faienza MF, Piaonte L, Ventura A, Oranger A, Carbone C, Benedetto AD, Colaianni G, Gigante M, Mori G, Guasaldo L, Colucci S, Cavallo L, Grano M. High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. Am J Physiol Endocrinol Metab 2013; 304: E546-E554 [PMID: 23299503 DOI: 10.1152/ajpendo.00535.2012]
6. Ventura A, Brunetti G, Colucci S, Oranger A, Ladisa F, Cavallo L, Grano M, Faienza MF. Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency. Biomed Res Int 2013; 2013: 250462 [PMID: 23484098 DOI: 10.1155/2013/250462]
7. Faienza MF, Brunetti G, Colucci S, Piaonte L, Ciccarelli M, Giordani L, Del Vecchio GC, D’Amore M, Albanese L, Cavallo L, Grano M. Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance. J Clin Endocrinol Metab 2009; 94: 2269-2276 [PMID: 19401376]
8. de Gregório LH, Lacatava PG, Melazzi AC, Russo LA. Glucocorticoid-induced osteoporosis. Arq Bras Endocrinol Metab 2006; 50: 793-801 [PMID: 17117304]
9. Pei L, Tontonoz P. Fat’s loss is bone’s gain. J Clin Invest 2004; 113: 805-806 [PMID: 15067310 DOI: 10.1172/JCI20042131]
10. Bennett CN, Ross SE, Longo KA, Bajnok L, Hemati N, Johnson KW, Harrison SD, MacDougald OA. Regulation of Wnt signaling during adipogenesis. J Biol Chem 2002; 277: 3098-3104 [PMID: 12055200 DOI: 10.1074/jbc.M204527200]
11. Gimble JM, Zvoncic S, Floyd ZE, Kassem M, Nuttall ME. Playing with bone and fat. J Cell Biochem 2006; 98: 251-266 [PMID: 16479859 DOI: 10.1002/jcb.20777]
12. Liu J, Farmer SR. Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Cell Biochem 2004; 94: 2269-2276 [PMID: 19401376]
13. Kang S, Bennett CN, Gerin I, Rapp LA, Hankenson KD, Macdougald OA. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem 2007; 282: 14515-14524 [PMID: 17351296 DOI: 10.1074/jbc.M700030200]
14. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005; 8: 739-750 [PMID: 15866164 DOI: 10.1016/j.devcel.2005.03.016]
15. Andrade AC, Nilsson O, Barnes KM, Baron J. Wnt gene expression in the post-natal growth plate: regulation with chondrocyte differentiation. Bone 2007; 40: 1361-1369 [PMID: 17357262 DOI: 10.1016/j.bone.2007.01.005]
16. Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci
Colaianii G et al. Wnt signaling involvement in bone-fat connection

LISA 2005; 102: 3324-3329 [PMID: 15728361 DOI: 10.1073/pnas.0408742102]

17 Guo J, Jin J, Cooper LF. Dissection of sets of genes that control the character of Wnt5a-deficient mouse calvarial cells. Bone 2008; 43: 961-971 [PMID: 18656562 DOI: 10.1016/j.bone.2008.06.011]

18 Bilkovski R, Schulte DM, Oberhauser F, Gomolka M, Udelhoven M, Hettich MM, Roth B, Heidenreich A, Gutschow C, Krone W, Laudes M. Role of WNT-5a in the determination of human mesenchymal stem cells to preadipocytes. J Biol Chem 2010; 285: 6170-6178 [PMID: 20032469 DOI: 10.1074/jbc.M109.054338]

19 Takada I, Mihara M, Suzawa M, Ohtake F, Kobayashi S, Igarashi M, Youn MY, Takeyama K, Nakamura T, Mezaki Y, Takezawa S, Yogiashi Y, Kitagawa H, Yamada G, Takada S, Minami Y, Shibuya H, Matsumoto K, Kato S. A histone lysine methyltransferase activated by non-canonical Wnt signaling suppresses PPAR-gamma transactivation. Nat Cell Biol 2007; 9: 1273-1285 [PMID: 17952062 DOI: 10.1038/ncb1647]

20 Chang J, Sonoyama W, Wang Z, Jin Q, Zhang C, Krebsbach PH, Giannobile W, Shi S, Wang CY. Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. J Biol Chem 2007; 282: 30938-30948 [PMID: 17720811 DOI: 10.1074/jbc.M702931200]

21 Moldes M, Zuo Y, Morrison RF, Silva D, Park BH, Liu J, Farmer SR. Peroxisome-proliferator-activated receptor gamma suppresses Wnt/beta-catenin signaling during adipogenesis. Biochem J 2003; 376: 607-613 [PMID: 12940789 DOI: 10.1042/BJ20030426]

22 Ross SE, Hemiati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, MacDougall OA. Inhibition of adipogenesis by Wnt signaling. Science 2000; 289: 950-953 [PMID: 10937998 DOI: 10.1126/science.289.5481.950]

23 Kanazawa A, Tsukada M, Kamiyama M, Yangamitono T, Nakajima M, Maeda S, Wnt5b partially inhibits canonical Wnt/beta-catenin signaling pathway and promotes adipogenesis in 3T3-L1 preadipocytes. Biochem Biophys Res Commun 2005; 330: 505-510 [PMID: 15796911 DOI: 10.1016/j.bbrc.2005.03.007]

24 Christy RJ, Yang VW, Ntambi JM, Geiman DE, Landschulz WH, Friedman AD, Nakabeppu Y, Kelly TJ, Lane MD. Differentiation-induced gene expression in 3T3-L1 preadipocytes. CCAAT/enhancer binding protein interacts with and activates the promoters of two adipocyte-specific genes. Genes Dev 1999; 3: 1323-1335 [PMID: 2606350 DOI: 10.1101/gad.3.9.1323]

25 Ducy P, Zhang R, Geoffrey V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-754 [PMID: 9182762 DOI: 10.1016/S0092-8674(00)80257-3]

26 Lecka-Czernik B, Gubri I, Moerman EJ, Lipshitz DA, Manolagas SC, Jilka RL. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR-gamma2. J Cell Biochem 1999; 74: 357-371 [PMID: 10412038 DOI: 10.1002/(SICI)1070-4644(19990901)74:4<357::AID-JBIC357>3.0.CO;2-I]

27 He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335-345 [PMID: 10585149]

28 Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004; 4: 61-70 [PMID: 14708026 DOI: 10.1038/nrc1254]

29 Fu M, Rao M, Bouras T, Wang C, Wu K, Zhang X, Li Z, Yao TP, Pestell RG. Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. J Biol Chem 2005; 280: 16934-16941 [PMID: 15713663 DOI: 10.1074/jbc.M500432200]

30 Krause C, Korchynskyi O, de Rouji K, Weidauer SE, de Grootse DJ, van Besooijen RL, Hatsell S, Economides AN, Mueller TD, Løwik CW, ten Diijke P. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 2010; 285: 41614-41626 [PMID: 20952383 DOI: 10.1074/jbc.M110.153890]

31 Park JR, Jung JW, Lee YS, Kang KS. The roles of Wnt antagonists Dkk1 and SFRP4 during adipogenesis of human adipose tissue-derived mesenchymal stem cells. Cell Prolif 2008; 41: 859-874 [PMID: 19040566 DOI: 10.1111/j.1600-065.x]

32 Gustafson B, Smith U. Activation of canonical wingless-type MMTV integration site family (Wnt) signaling in mature adipocytes increases beta-catenin levels and leads to cell dedifferentiation and insulin resistance. J Biol Chem 2010; 285: 14031-14041 [PMID: 20179324 DOI: 10.1074/jbc.M110.102855]

33 Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostino D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszcy Z. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008; 23: 860-869 [PMID: 18269310 DOI: 10.1359/jbmr.081206]

34 Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shallowb V, Tipton B, Haldanek R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszcy Z. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24: 578-588 [PMID: 19049536 DOI: 10.1359/jbmr.081206]

35 Tian X, Setterberg BB, Li X, Paszcy Z, Ke HZ, Joe WS. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 2010; 47: 529-533 [PMID: 20561907 DOI: 10.1016/j.bone.2010.05.032]

36 Morse LR, Sudhakar S, Danilack V, Tun C, Lazzari A, Gaagnon DR, Garshick E, Battaglino RA. Association between sclerostin and bone density in chronic spinal cord injury. J Bone Miner Res 2012; 27: 352-359 [PMID: 22006831 DOI: 10.1002/jbmr.546]

37 Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuys W, Van Den Ende J, Willems P, Alves-AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foerzner D, Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10: 537-543 [PMID: 11815758 DOI: 10.1093/hmg/10.5.537]

38 Mirza FS, Padhi ID, Raisg LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 2010, 95: 1991-1997 [PMID: 20516921 DOI: 10.1210/jc.2009-2283]

39 Urano T, Shiraki M, Ouchi Y, Inoue S. Association of circulating sclerostin levels with fat mass and metabolic disease-related markers in Japanese postmenopausal women. J Clin Endocrinol Metab 2012; 97: E1473-E1477 [PMID: 22639287 DOI: 10.1210/jc.2012-1218]
